Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis

AIDS

Volumn 21, Issue 2, 2007, Pages 199-205

  Duran, Adriana S ^a   Losso, Marcelo H ^a   Salomón, Horacio ^b   Harris, D Robert ^c   Pampuro, Sandra ^b   Soto Ramirez, Luis E ^d   Duarte, Geraldo ^e   De Souza, Ricardo S ^f   Read, Jennifer S ^g  

^a HOSPITAL RAMOS MEJÍA   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c WESTAT   (United States)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f University of Caxias Do sul   (Brazil)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antiretroviral drug resistance; HIV 1 and pregnancy; HIV 1 mutations; Mother to child transmission

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PREGNANT WOMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; TREATMENT DURATION; VIROLOGY; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD;

EID: 33845949971     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328011770b     Document Type: Article

References (19)

1. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335:1621-1629.
2. Ioannidis JPA, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001; 183:539-545.
3. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-1180.
4. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose NVP compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial. Lancet 1999; 354:795-802.
5. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-228.
6. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484-494.
7. Centers for Disease Control and Prevention. US Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and Interventions to reduce perinatal HIV-1 transmission in the United States. MMWR 2005; 47:1-30. (Most recent revision of the guidelines available at www.aidsinfo.nih.gov.).
8. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:458-465.
9. Read J, Cahn P, Losso M, Pinto J, Joao E, Duarte G, et al. A prospective cohort study of HIV-1-infected pregnant women and their infants in Latin America and the Caribbean: The NICHD International Site Development Initiative (NISDI) Perinatal Study. Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2005 [abstract 790].
10. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41:1-19.
11. Johnson VA, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutation in HIV-1: Fall. Top HIV Med 2005; 13:125-131.
12. Freeman GH, Halton JH. Note on an exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 1951; 38:141-149.
13. Chokephaibulkit K, Chaisilwattana P, Vanprapar N, Phongsamarta W, Sutthentc R. Lack of resistant mutation development after receiving short-course zidovidine plus lamivudine to prevent mother to child HIV transmission. AIDS 2005; 19: 1231-1232.
14. Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005; 19:63-67.
15. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, Berrebi A, Benifla JL, Burgard M, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285:2083-2093.
16. Kearney M, Palmer S, Maldarelli F, Bixby C, Bazmi H, Rock D, et al. Single-genome sequencing is more sensitive than standard genotype analysis for detection of HIV-1 drug-resistance mutations. Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004 [abstract 695].
17. Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
18. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322:1087-1088.
19. Watts DH, Lambert J, Stiehm ER, Harris DR, Bethel J, Mofenson L, et al., for the PACTG 185 Study Team. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr 2003; 33:585-593.